India Chooses Vaccine Diplomacy in Hegemony Race
India has offered clinical trials to Pakistan of home-grown Covid-19 vaccine that has been developed by Hyderabad-based Bharat Biotech
India has decided to bring vaccine diplomacy into use to establish hegemony in the region as a Hyderabad-based pharmaceutical company Bharat Biotech Company will offer Pakistan to conduct clinical trials of its vaccine against novel coronavirus.
The National Health Ministry will review technical aspects of the process once the offer is extended.
So far, more than 9.7 million people have been infected with novel coronavirus in India while over 141,000 people have succumbed to the pandemic virus.
Besides Pakistan, India has also offered clinical trials of home-grown coronavirus vaccine to members of the South Asian Association for Regional Cooperation (SAARC).
Sources in the government told News360 that Biotech Company is the first Indian pharmaceutical company to start clinical trials. It is located in Hyderabad.
BioTech has established some 12 centers for clinical trials of its vaccine across India.
Some 26,000 volunteers have registered themselves for getting vaccine shots while it would be tested on some 20,000 volunteers in two phases.
The company got recognition as it invented a vaccine against Swine Flu (H1N1) while it wants to wear another feather in its cap by launching the Covid-19 vaccine before August 14 in India.
The pharmaceutical company will complete clinical trials of its homegrown vaccine by July 2020.
The company has the support of the Indian Council of Medical Research (ICMR) while Central Drugs Standard Organizations has given a green-go for clinical trials too.
Read Also
Coronavirus Vaccine Procurement Dim For Poor Nations
Bharat Biotech has experience of developing 16 different vaccines against different diseases while its vaccine against Rotavirus is approved by World Health Organization (WHO).
